The Community Services Advisory Council is composed of individuals with a variety of experiences with ALS who provide input and perspectives to support ALS Canada in improving the journey of people and families living with ALS in Ontario. The Council serves in an advisory capacity to the Board, making recommendations for client service program delivery, community partnerships and provincial advocacy according to the strategic priorities.
Co-Chairs
Kim Barry Director, Community Services, ALS Canada
Lisa Flaifel Vice President, General Medicine, Bayer
Scientific and Medical Advisory Council
The Scientific and Medical Advisory Council provides strategic advice to the Board and management of ALS Canada to ensure all research activities contribute to the vision of ALS Canada, are aligned with the organization’s strategic priorities, are informed by best practices, and are carried out with integrity. The Council also facilitates collaboration within the Canadian ALS research community and supports the Canadian ALS research community’s involvement in international initiatives.
Chair
Christine Vande Velde, PhD
ALS Canada Board Member; Associate Professor, Université de Montréal
Turgay Akay, PhD
Dalhousie University
Vanina Dal Bello-Haas, PhD, PT
McMaster University
François Gros-Louis, PhD
Université Laval
Wendy Johnston, MD
University of Alberta
Hanns Lochmüller, MD, PhD
University of Ottawa
Cali Orsulak, BscPharm, BCPS, CDE
Patient Community Representative
Robin Parks, PhD
University of Ottawa
Gerald Pfeffer, MD, PhD
University of Calgary
Janice Robertson, PhD
University of Toronto
Kerri Schellenberg, MD
University of Saskatchewan
Paula Trefiak
Patient Community Representative
EX-OFFICIO
Colleen Doyle – Manager, Research & CALS, ALS Canada
Patrick Nelson – Chair, ALS Canada Board; Principal, Santis Health; family member of a loved one who had ALS
David Taylor – VP Research, ALS Canada
Advocacy Committee
The Advocacy Committee provides professional and personal insight to the Board of Directors and to Staff to help advance our advocacy program. This includes advising the organization on which ALS advocacy priorities to bring forward to government and how to achieve results most effectively. The committee also ensures that ALS Canada’s advocacy efforts align with our strategic plan and are undertaken with the utmost integrity. Members of this committee have a variety of experiences including people and families affected by the disease, government relations experts, health sector professionals, and leading academic ALS researchers.
Co-Chairs
Richard Ellis
Executive Coach, global business executive & communications expert
Carmen Cels Director, People & Culture, Roche Canada; and caregiver to a loved one with to ALS
Mike Cels Person Living with ALS, Retired from Pharmaceutical Sector
Ryan Clarke (ex-officio) Partner (Division Lead, Advocacy and PR), CRG Eversana Canada Inc.
Lisa Flaifel Vice President, General Medicine, Bayer
Dr. Angela Genge,MD, FRCP(C) Director of the ALS Clinic and the Clinical Research Unit, The Neuro (Montreal Neurological Institute-Hospital)
Sherry MacLauchlan Government Relations and Public Affairs Professional
Stephanie Mazzei Consultant related to therapeutics, diagnostics, and digital health in cancer care
Tammy Moore (ex-officio, Staff) CEO, ALS Canada
Patrick Nelson (ex-officio) Chair, ALS Canada Board; Principal, Santis Health; family member of a loved one who had ALS
Kris Noakes
Community Advocate, living with ALS
Lauren Poplak (ex-officio, Staff) Manager, Public Affairs & Communications, ALS Canada
Dr. Karin Schnarr Director, MBA Programs; Associate Professor, Policy & Law at the Lazaridis School of Business & Economics at Wilfrid Laurier University
